Trials / Completed
CompletedNCT01177267
Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions(DDI) Among Osteoarthritis Patients
Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Osteoarthritis Patients Taking Opioid Analgesics and Associated Economic Outcomes
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 10,000 (planned)
- Sponsor
- NEMA Research, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Using a retrospective database analysis, OA patients taking at least one CYP450-metabolized opioid (codeine, fentanyl, hydrocodone, methadone, oxycodone, or tramadol) and at least one other prescription drug metabolized via the CYP450 system were evaluated for an incident drug-drug exposure (DDE), which places them at risk for experiencing a pharmacokinetic drug-drug interaction (DDI).
Conditions
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2010-12-01
- Completion
- 2011-01-01
- First posted
- 2010-08-06
- Last updated
- 2012-05-01
Source: ClinicalTrials.gov record NCT01177267. Inclusion in this directory is not an endorsement.